Document is current
Any future updates will be listed below
-
Authors
Gubbiotti, Maria A.
McCutcheon, Ian E.
Rao, Priya
Genovese, Giannicola
Wang, Linghua
Tarasov, Artem
Putintsev, Vladislav
Berlinski, Amber
Stupichev, Danil
Kriukov, Kirill
Davitavyan, Suren
Salem, Basim
Sarachakov, Alexander
Lebedev, Dmitry
Hensley, Michael
Bagaev, Alexander
Paradiso, Francesca
Kushnarev, Vladimir
Khegai, Gleb
Tannir, Nizar M.
Msaouel, Pavlos
-
Funding
Funding for this research was provided by:
National Cancer Institute (P30 CA016672, P30 CA016672)
U.S. Department of Defense (RA230062)
Finneran Family Endowment
Andrew Sabin Family Foundation
Translational Research Partnership Award (KC200096P1)
Advanced Discovery Award Kidney Cancer Association
V Foundation
MD Anderson Physician Scientist Award
- License Information
-
More Information
Article History
Received: 30 October 2024
Accepted: 7 January 2025
First Online: 20 January 2025
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center (protocols #2024 − 1035 and PA11-1045).
: A waiver of consent was granted by the institutional review board which is available upon request.
: PM has received honoraria for service on a Scientific Advisory Board for Mirati Therapeutics, Bristol Myers Squibb, and Exelixis; consulting for Axiom Healthcare Strategies; non-branded educational programs supported by DAVA Oncology, Exelixis and Pfizer; and research funding for clinical trials from Regeneron Pharmaceuticals, Takeda, Bristol Myers Squibb, Mirati Therapeutics, Gateway for Cancer Research, and the University of Texas MD Anderson Cancer Center.
